Evaluation of Inflammasome Gene Polymorphisms in Periodontitis Patients
NCT ID: NCT06465095
Last Updated: 2024-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
240 participants
OBSERVATIONAL
2024-07-01
2025-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Pregnancy-Associated Plasma Protein-A and Interleukin-6 Gene Polymorphisms in Patients With Periodontitis
NCT06540755
Vitamin D Receptor, Interleukin-1A and Interleukin-1B Gene Polymorphisms in Periodontitis
NCT04806971
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases
NCT06075680
Frequency Of MCP-1 And CCR2 Gene Polymorphisms And Its Effect On Gene Expression In Patients With AgP
NCT02817568
Effect of Periodontal Therapy on Biomarkers in Periodontitis
NCT05005923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Progression rate, onset age, and severity of periodontal disease are influenced by some modifiable or non-modifiable risk factors present in the host. Genetic polymorphisms are non-modifiable risk factors for periodontitis. Variations in inflammasome genes may be determinants in the development of periodontal disease by leading to diversity in inflammatory markers.
Sample size is determined based on a previous study which analyzes the effect of NLRP3 gene polymorphism on periodontitis susceptibility. For rs4612666 group, with an α value of 0.05 and a power of 80%, it is determined that there should be 80 participants in each group. Totally 240 patients are included (80 periodontally healthy, 80 Stage III Grade B periodontitis, 80 Stage III Grade C periodontitis). The whole mouth clinical periodontal examination includes measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. Periodontal diagnosis of each patient has been made according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Healthy group includes individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP \< 10%, probing depth ≤ 3 mm. Stage III Grade B periodontitis patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 and Stage III Grade C patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is \>1.
Sample Collection and DNA Isolation and Genotyping A total of 5 mL of blood is collected from the antecubital fossa by venepuncture method from each participants and stored at -80°C until analysis day. DNA isolation has been made using genomic DNA kits. rs4612666, rs75985579, and rs2793845 SNP regions are detected from DNA material using Real-Time PCR device genotyping kits.
Statistical analysis has been performed with standard statistical software package by selecting appropriate tests.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy
Individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP \< 10%, probing depth ≤ 3 mm.
Baseline
Measurements and sampling
Stage III Grade B Periodontitis
Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 will be included.
Baseline
Measurements and sampling
Stage III Grade C Periodontitis
Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is \>1 will be included.
Baseline
Measurements and sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baseline
Measurements and sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients between the ages of 18 and 65
* individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses
Exclusion Criteria
* Usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months.
* Periodontal treatment within the preceding 6 months.
* Pregnant/ lactating/ postmenopausal females.
* Current orthodontic treatment.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marmara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Marmara University
Istanbul, Maltepe, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-2023-1700
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.